Zobrazeno 1 - 10
of 75
pro vyhledávání: '"Michel Andrejak"'
Autor:
Alice Séjourné, Sabine Noal, Mathieu Boone, Céline Bihan, Marion Sassier, Michel Andrejak, Bruno Chauffert
Publikováno v:
Case Reports in Oncology, Vol 7, Iss 3, Pp 669-672 (2014)
Ifosfamide is used in the treatment of sarcomas and other tumors. It sometimes provokes encephalopathy, which is a serious complication even if it is usually reversible within 48-72 h after drug cessation. Ifosfamide is required to be activated by he
Externí odkaz:
https://doaj.org/article/503a823b769e407a94c3ad53cfa26eb1
Publikováno v:
Sang thrombose vaisseaux. 30:108-112
Autor:
Pierre-Vladimir Ennezat, Raphaëlle-Ashley Guerbaai, Denis Vital-Durand, Sylvestre Maréchaux, Michel Andrejak, Shona Cosgrove, Thierry H. Le Jemtel, Hélène Bouvaist
Publikováno v:
Archives of Cardiovascular Diseases. 110:413-419
Nowadays, guidelines are derived from the findings of randomized controlled therapeutic trials. However, an overall significant P value does not exclude that some patients may be harmed by or will not respond to the therapeutic agent being studied. T
Autor:
Emuri Abe, Giampiero Bricca, Youssef Bennis, Anne-Sophie Lemaire-Hurtel, M.-C. Quinton, Sandra Bodeau, Jean-Claude Alvarez, Michel Andrejak
Publikováno v:
Toxicologie Analytique et Clinique. 28:32-37
Resume La colchicine est un alcaloide utilise pour ses proprietes anti-inflammatoires en prophylaxie ou dans le traitement de la crise aigue de goutte et dans d’autres maladies a composante inflammatoire telles que la fievre mediterraneenne familia
Autor:
Céline Bihan, Bruno Chauffert, Alice Séjourné, Mathieu Boone, Sabine Noal, Marion Sassier, Michel Andrejak
Publikováno v:
Case Reports in Oncology
Case Reports in Oncology, Vol 7, Iss 3, Pp 669-672 (2014)
Case Reports in Oncology, Vol 7, Iss 3, Pp 669-672 (2014)
Ifosfamide is used in the treatment of sarcomas and other tumors. It sometimes provokes encephalopathy, which is a serious complication even if it is usually reversible within 48-72 h after drug cessation. Ifosfamide is required to be activated by he
Autor:
Sylvestre Maréchaux, Catherine Szymanski, Marcel Peltier, Michel Andrejak, Christophe Tribouilloy
Publikováno v:
Pharmacoepidemiology and Drug Safety. 23:679-686
Benfluorex is responsible for the development of restrictive valvular regurgitation due to one of its metabolites, norfenfluramine. The 5-HT2B receptor, expressed on heart valves, acts as culprit receptor for drug-induced valvular heart disease (VHD)
Autor:
Sandra Bodeau, A. Knapp, Valérie Gras, Michel Andrejak, Jean-Claude Alvarez, C. Presne, Aurélien Cheyroux, Anne-Sophie Lemaire-Hurtel, Kamel Masmoudi
Publikováno v:
Toxicologie Analytique et Clinique. 26:27-31
Resume Objectifs Le baclofene est un myorelaxant d’action centrale, analogue du GABA, prescrit dans le traitement de la spasticite. Nous rapportons le cas d’un patient de 60 ans, insuffisant renal chronique, traite quotidiennement par 15 mg de ba
Autor:
Michel Andrejak, Guillaume Deslandes, Sandra Bodeau, Céline Verstuyft, Anne-Sophie Lemaire-Hurtel, Taieb Chouaki, Régis Bouquié, Youssef Bennis, Bérangère Gruson
Publikováno v:
British Journal of Clinical Pharmacology. 80:782-784
Publikováno v:
Archives of Cardiovascular Diseases. 106(5):333-339
SummaryNumerous reports have shown an unquestionable association between fibrotic valve disease and the following drugs: ergot alkaloids (such as methysergide and ergotamine), ergot-derived dopaminergic agonists (such as pergolide and cabergoline) an
Autor:
Sylvestre Maréchaux, Antoine Jeu, Yannick Jobic, Dan Rusinaru, Michel Andrejak, Christophe Tribouilloy
Publikováno v:
La Presse Médicale. 40:1008-1016
Key points Benfluorex is responsible of restrictive organic valvular regurgitations via one of its metabolites, the norfenfluramine. It has been withdrawn from the european market in June 2010. In France, about five millions of people have been expos